Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (69621)	2/19/2001 11:14:44 PM
From: Casaubon	Respond to of 99985

down regulation of TNF-alfa have more widespread application than those two disease areas. In any event: Immunex said total revenues for the quarter rose to $250.7 million, from $162.6 million in the fourth quarter of 1999. Enbrel sales rose to $194.1 million in the latest quarter, a gain of 65 percent over the same period in 1999 and 13 percent increase over the third quarter of 2000. not too shabby for a "rare disease", which is production capacity constrained. Also, this drug is actually reversing the joint destruction. So, perhaps previously debilitated, worthless, hopeless people, might be able to give us something back. Lord knows, they owe us. <ggg>